These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 30946323

  • 1. Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.
    Kim I, Kim A, Lee CH, Lee G, Kim A, Jo EJ, Kim MH, Mok J, Lee K, Kim KU, Park HK, Lee MK, Eom JS.
    Medicine (Baltimore); 2019 Apr; 98(14):e14972. PubMed ID: 30946323
    [Abstract] [Full Text] [Related]

  • 2. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS, Kim SJ, Kang JH, Han DH, Jung JI, Lee KY.
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [Abstract] [Full Text] [Related]

  • 3. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 4. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A.
    Cancer Cytopathol; 2017 Dec 01; 125(12):896-907. PubMed ID: 29024471
    [Abstract] [Full Text] [Related]

  • 5. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
    Xu H, Lin G, Huang C, Zhu W, Miao Q, Fan X, Wu B, Zheng X, Lin X, Jiang K, Hu D, Li C.
    Sci Rep; 2017 Dec 05; 7(1):16956. PubMed ID: 29209070
    [Abstract] [Full Text] [Related]

  • 6. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
    Shigeta N, Murakami S, Yokose T, Isaka T, Shinada K, Nagashima T, Adachi H, Shigefuku S, Murakami K, Miura J, Kikunishi N, Watabe K, Saito H, Ito H.
    Thorac Cancer; 2024 Jun 05; 15(17):1343-1349. PubMed ID: 38698758
    [Abstract] [Full Text] [Related]

  • 7. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A, Siegel L, Freese R, Racila E, Stewart J, Amin K.
    Diagn Cytopathol; 2021 Mar 05; 49(3):355-362. PubMed ID: 33142053
    [Abstract] [Full Text] [Related]

  • 8. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
    Koomen BM, Vreuls W, de Boer M, de Ruiter EJ, Hoelters J, Vink A, Willems SM.
    Histopathology; 2021 Oct 05; 79(4):480-490. PubMed ID: 33772818
    [Abstract] [Full Text] [Related]

  • 9. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM.
    J Thorac Oncol; 2017 Feb 05; 12(2):208-222. PubMed ID: 27913228
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M, Patrucco F, Gavelli F, Airoldi C, Sciortino G, Chiaramonte C, Rena O, Balbo PE, Boldorini RL.
    Cancer Cytopathol; 2020 Aug 05; 128(8):580-588. PubMed ID: 32463583
    [Abstract] [Full Text] [Related]

  • 11. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr 05; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 12. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
    Velcheti V, Patwardhan PD, Liu FX, Chen X, Cao X, Burke T.
    PLoS One; 2018 Apr 05; 13(11):e0206370. PubMed ID: 30408065
    [Abstract] [Full Text] [Related]

  • 13. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
    Fujimoto D, Sato Y, Uehara K, Ishida K, Fukuoka J, Morimoto T, Kawachi H, Mori R, Ito M, Teraoka S, Nagata K, Nakagawa A, Otsuka K, Imai Y, Tomii K.
    J Thorac Oncol; 2018 Mar 05; 13(3):377-386. PubMed ID: 29233789
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK, Midthun DE, Mullon JJ, Kern RM, Nelson DR, Edell ES, Schiavo DN, Jett JR, Aubry MC.
    Chest; 2018 Oct 05; 154(4):827-837. PubMed ID: 30059678
    [Abstract] [Full Text] [Related]

  • 15. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A, Morikawa K, Inoue T, Miyazawa T, Hoshikawa M, Takagi M, Mineshita M.
    BMC Cancer; 2019 Jun 07; 19(1):546. PubMed ID: 31174496
    [Abstract] [Full Text] [Related]

  • 16. Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Stoy SP, Rosen L, Mueller J, Murgu S.
    Cancer Cytopathol; 2018 Feb 07; 126(2):122-128. PubMed ID: 29053224
    [Abstract] [Full Text] [Related]

  • 17. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
    Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara H, Yamamoto N, Sasada S, Watanabe S, Asamura H, Tamura T, Ohe Y.
    Clin Lung Cancer; 2015 Sep 07; 16(5):385-90. PubMed ID: 25937270
    [Abstract] [Full Text] [Related]

  • 18. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
    Maule JG, Clinton LK, Graf RP, Xiao J, Oxnard GR, Ross JS, Huang RSP.
    J Immunother Cancer; 2022 Oct 07; 10(10):. PubMed ID: 36302564
    [Abstract] [Full Text] [Related]

  • 19. Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
    Lou SK, Ko HM, Kinoshita T, MacDonald S, Weiss J, Czarnecka-Kujawa K, Boerner SL, Yasufuku K, Tsao MS, Schwock J.
    Acta Cytol; 2020 Oct 07; 64(6):577-587. PubMed ID: 32599583
    [Abstract] [Full Text] [Related]

  • 20. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II.
    JAMA Oncol; 2017 Aug 01; 3(8):1051-1058. PubMed ID: 28278348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.